Point Of Care Infectious Disease Testing Market (2026- 2033)

Point Of Care Infectious Disease Testing Market Summary

The global point of care infectious disease testing market size was valued at USD 13.4 billion in 2025 and is projected to grow from USD 14.0 billion in 2026 to USD 16.9 billion by 2033, at a CAGR of 2.7% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 42.6% in 2025. The market is driven by the rising infectious diseases, demand for precise diagnostics tools and technological advancements such as molecular diagnostics & agglutination test.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The rising contagious disease and increasing aging population along with the supportive government policies promoting the adoption of point of care (POC) testing are the factors likely to fuel the market growth during the forecast period. The rising demand for diagnostic tools is increasing due to the increasing number of infectious diseases such as HIV, hepatitis, and tuberculosis. These point-of-care tests are becoming more common as many illnesses need to be found early to be treated as soon as possible.

To learn more about this report, Download Free Sample Report

There is an increasing shift towards rising communicable diseases and rise in home healthcare preferred by many patients, especially the elderly and individuals with chronic conditions such as heart disease, diabetes and cancer. This shift contributes to POC diagnostics tools by allowing tests to be done outside typical medical places, even at home. This brings benefits like convenience, lower expenses, and more control for patients. Easy-to-use POC tests give accurate results, letting patients keep tabs on their health and require fewer doctor hospital visits.

Market Dynamics

The global point of care infectious disease testing market is experiencing steady growth driven by the increasing need for rapid diagnosis, expanding decentralized healthcare services, and continuous innovation in molecular and immunoassay-based testing technologies. Healthcare providers are increasingly adopting point of care testing to reduce diagnostic turnaround times, support immediate treatment decisions, and improve patient outcomes across hospitals, clinics, pharmacies, and community healthcare settings. The growing prevalence of respiratory infections, sexually transmitted infections, and vector borne diseases continues to strengthen demand for accessible diagnostic solutions. Industry participants are also expanding their product portfolios to improve testing accuracy and workflow efficiency. For instance, in January 2025, Roche received U.S. FDA 510(k) clearance and CLIA waiver for its cobas liat CT/NG and CT/NG/MG molecular assays, expanding its point of care infectious disease testing portfolio for sexually transmitted infections and enabling rapid PCR based diagnosis in decentralized healthcare settings. The increasing focus on early disease detection, public health surveillance, and regulatory support is expected to sustain market expansion throughout the forecast period.

Analyst Perspective

The point of care infectious disease testing market is expected to witness sustained growth as healthcare systems continue to prioritize rapid diagnosis, decentralized care, and timely clinical decision making. Increasing adoption of molecular point of care platforms, multiplex diagnostic assays, and digital connectivity is improving diagnostic accuracy while expanding testing beyond traditional laboratory settings. Regulatory support, expanding infectious disease screening programs, and growing investments in primary healthcare infrastructure are further strengthening market demand. In addition, continuous product innovation and strategic collaborations among leading manufacturers are expected to accelerate commercialization of advanced testing solutions, enabling broader access to reliable infectious disease diagnostics across both developed and emerging markets.

Disease Insights

Based on disease, the COVID-19 segment led the market with the largest revenue share of 92.8% in 2025. This high percentage can be attributed to the rising number of infectious cases and need for fast and accessible diagnostics testing solutions. Point-of-care tests were crucial as they delivered results quickly, allowing for rapid identification and management of cases. These tests could be done outside traditional labs, like in clinics or even at home, making them highly convenient.

The pneumonia or streptococcus associated infections segment is anticipated to witness the fastest CAGR during the forecast period, owing to the rising cases of communicable disease and developments of new drugs in treatment of disease. Pneumococcal disease is caused by bacteria called Streptococcus pneumonia. Streptococcus bacteria are very common and can be spread easily through an infected person owing to rapid diagnosis importance to the disease. POC test provides faster results, allowing for faster treatments.

Type Insights

Based on Type, the POC rapid diagnostic single-test segment led the market with the largest revenue share of 76.0% in 2025, owing to rising number of patients due to infectious disease and advancements in molecular testing. Molecular tests are highly accurate and capable of detecting genetic materials. Molecular diagnostics devices deliver faster and accurate results, which is essential for patient care and helpful for doctors for quicker treatment decisions.

Lateral flow immunoassay is expected to register the fastest CAGR of 5.7% during the forecast period. The growth can be attributed to increasing prevalence of infectious diseases such as respiratory disease and technological advancements in point of care diagnostics device. A lateral flow immunoassay is a diagnostic device that confirms the presence of substance from a sample. Lateral flow tests are portable and lightweight and are great for point of care settings such as homes, offices and remote regions with small healthcare facilities. The rise in consumer demand for lateral flow immunoassay devices is likely to drive the growth due to its several benefits.

End Use Insights

Based on end-use, the clinics segment led the market with the largest revenue share of 37.5% in 2025. The growth can be attributed to increasing establishments of point of care diagnostics laboratory centers and rising number of communicable diseases. Clinics play a crucial role serving as an important point of care center for treating and testing patients for various diseases such as TB, etc.

To learn more about this report, Download Free Sample Report

The home segment is projected to grow at the fastest CAGR of 5.5% over the forecast period, owing to increasing adoption of point of care testing among geriatric population and increasing emphasis on personalized and preventive home care facilities. Home care provides patients with convenience and accessibility. Easy-to-use tools for diagnosing infectious diseases at home allow patients to test themselves without requiring healthcare professionals. Moreover, convenience encourages people to manage their health better by getting tested quickly, which helps find and treat infectious diseases early.

Regional Insights

North America dominated the point of care infectious disease testing market with the largest revenue share of 42.6% in 2025 owing to the rising number of infectious and advancements in technology. The presence of advanced healthcare infrastructure, high adoption of point of care testing and home to some of largest companies operating in point of care infectious disease testing market are some of the factors propelling the market growth. Moreover, the rising healthcare expenditure and increasing geriatric population in countries such as U.S. Canada & Mexico is boosting the region growth.

To learn more about this report, Download Free Sample Report

U.S. Point Of Care Infectious Disease Testing Market Trends

The point of care infectious disease testing market in the U.S. held the largest share in the North America region in 2025 due to rising number of infectious in the nation. According to centers for disease control and prevention, there were more than 9,500 cases of TB registered in 2023, a 16% increase from 2022. Furthermore, the country has a robust infrastructure for research and development and a better advanced healthcare system.

Europe Point Of Care Infectious Disease Testing Market Trends

Europe point of care infectious disease testing market was identified as a lucrative region in 2023. The growth can be attributed to the increasing prevalence of infectious disease. Rising healthcare expenditure and growing awareness among people for point of care testing is driving the region’s growth. The private sector is playing a crucial role in development of new diagnostics devices which are easy to use and convenient.

The UK point of care infectious disease testing market is expected to grow rapidly in the coming years due to increasing number of communicable disease and public health initiatives. The UK government focuses strong emphasis on public health and preventing health issues, with support from organizations such as National Health Service. Furthermore, the health initiatives and research & development by the UK government is likely to contribute to the growth in the country.

The point of care infectious disease testing market in Germany held a substantial market share in 2023 owing to increasing geriatric population and rising prevalence of infectious disease. The country possesses robust healthcare infrastructure and ranks 3^rd in healthcare innovation. Moreover, the government policy and initiatives for healthcare system such as mandatory health insurance for all residents is likely to propel the region’s growth.

Asia Pacific Point Of Care Infectious Disease Testing Market Trends

Asia Pacific market point of care infectious disease diagnostics is anticipated to witness the fastest CAGR of 5.0% during the forecast period. This growth is due to the significantly increasing population in the region and rising infectious diseases. Infectious diseases are more common compared to other places and infectious diseases spread easily due to large and rising geriatric population in countries like China, Japan and India. The rising demand for fast and easy ways to diagnose the disease is fueling the growth.

The China point of care infectious disease testing market held a substantial market share in 2023 driven by large population and rising cases of infectious diseases such as TB, and hepatitis. The adoption of advanced diagnostic medical devices such as molecular diagnostics and lateral flow immunoassay are fueling the country’s growth.

The point of care infectious disease testing market in India is expected to witness significant growth during the forecast period, owing to the increasing population, rise in prevalence of communicable disease in children under age of 3 and population over the age of 65.

Key Point Of Care Infectious Disease Testing Company Insights

Some of the key companies in the point of care infectious disease testing market include Abbott; Thermo Fisher Scientific Inc; F. Hoffmann-La Roche Ltd; Siemens Healthineers; Quest Diagnostics Incorporated. Organizations are focusing on increasing customer base to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives, such as mergers and acquisitions, and partnerships with other major companies. 

Recent Developments

• In January 2024, Roche acquired LumiraDx’s point of care technology. The LumiraDx’s platform includes a range of immunoassay and clinical chemical tests. The addition of LumiraDx’s to Roche may enable the company to transform testing at the point of care.

• In February 2023, Thermo Fisher partnered with Mylab, announced to launch made-in-India RTPCR kits for infectious disease in India. Mylab in partnership with Thermo Fisher aims to access of the test to a greater portion of the population in India as well as the world.

Global Point Of Care Infectious Disease Testing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global point of care infectious disease testing market report based on technology, disease, end use, and region:

To learn more about this report, Download Free Sample Report

• Technology Outlook (Revenue, USD Billion, 2021 - 2033)

  • Lateral Flow Immunoassay

  • Agglutination Test

  • Flow-through test/Immunoconcentration Assay

  • Molecular Diagnostics

  • Others

• Disease Outlook (Revenue, USD Billion, 2021 - 2033)

  • HIV POC

  • Clostridium Difficile POC

  • HBV POC

  • Pneumonia Or Streptococcus Associated Infections

  • Respiratory Syncytial Virus (RSV) POC

  • HPV POC

  • Influenza/Flu POC

  • HCV POC

  • MRSA POC

  • TB & Drug-resistant TB POC

  • HSV POC

  • COVID-19

  • Other Infectious Diseases

• End Use Outlook (Revenue, USD Billion, 2021 - 2033)

  • Clinics

  • Hospitals

  • Home

  • Assisted Living Healthcare Facilities

  • Laboratory

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The point of care infectious disease testing market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each point of care infectious disease testing quantified using the revenue-capture definitions in the table below.

Estimation Model

The market size was estimated using a bottom up approach by identifying key manufacturers of point of care infectious disease testing products, benchmarking their product portfolios, and analyzing revenue generated from relevant diagnostic platforms. Market estimates were further validated through technology wise adoption rates, patient utilization patterns, company market share analysis, and primary interviews with industry experts to ensure accurate market sizing and forecasting.

Delivered Customizations

This report has been delivered with the following In-depth customizations